NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free MAIA Stock Alerts $2.20 -0.28 (-11.29%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.15▼$2.5150-Day Range N/A52-Week Range$0.82▼$4.25Volume354,822 shsAverage Volume442,375 shsMarket Capitalization$31.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get MAIA Biotechnology alerts: Email Address MAIA Biotechnology MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.49Based on 7 Articles This WeekInsider TradingAcquiring Shares$200,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.47 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for MAIA Biotechnology. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.23% of the float of MAIA Biotechnology has been sold short.Short Interest Ratio / Days to CoverMAIA Biotechnology has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MAIA Biotechnology has recently increased by 30.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMAIA Biotechnology does not currently pay a dividend.Dividend GrowthMAIA Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MAIA. Previous Next 2.0 News and Social Media Coverage News SentimentMAIA Biotechnology has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for MAIA Biotechnology this week, compared to 1 article on an average week.Search Interest31 people have searched for MAIA on MarketBeat in the last 30 days. This is an increase of 244% compared to the previous 30 days.MarketBeat Follows9 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MAIA Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $200,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders56.97% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.65% of the stock of MAIA Biotechnology is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of MAIA Biotechnology is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MAIA Biotechnology is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMAIA Biotechnology has a P/B Ratio of 73.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA)MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.Read More MAIA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MAIA Stock News HeadlinesMarch 16, 2024 | insidertrades.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Buys $199,999.80 in StockMarch 28, 2024 | investing.comMAIA Biotechnology directors buy shares amid development pushMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 28, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro GuerreroMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces $1.33 Million Private PlacementMarch 22, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private PlacementMarch 21, 2024 | businesswire.comMAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory BoardMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 16, 2024 | finance.yahoo.comDirector Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA)March 14, 2024 | msn.comMAIA Biotechnology rises 3% on $2.92M private placementMarch 7, 2024 | finance.yahoo.comMAIA Biotechnology to Participate in the 36th Annual ROTH ConferenceMarch 7, 2024 | investing.comMAIA Biotechnology nears end of Phase 2 cancer trialMarch 6, 2024 | markets.businessinsider.comMAIA Announces Positive Data From Phase 2 THIO Clinical Trial For NSCLC; Stock Rises 8%March 6, 2024 | finance.yahoo.comMAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual MeetingMarch 6, 2024 | businesswire.comMAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual MeetingMarch 6, 2024 | businesswire.comMAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer PatientsMarch 5, 2024 | finance.yahoo.comMAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to ShareholdersFebruary 27, 2024 | globenewswire.comMAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific AdvisorFebruary 23, 2024 | msn.comMAIA Biotechnology concludes subject enrolment in NSCLC therapy trialFebruary 22, 2024 | finanznachrichten.deMAIA Biotechnology, Inc.: MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung CancerFebruary 22, 2024 | globenewswire.comMAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung CancerFebruary 8, 2024 | benzinga.comLatest News for MAIA Biotechnology Stock (AMEX:MAIA)February 7, 2024 | stockhouse.comMAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung CancerFebruary 6, 2024 | benzinga.comNovel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDAJanuary 31, 2024 | msn.comMAIA Biotechnology Patent Boosts Cancer Treatment PotentialJanuary 24, 2024 | finance.yahoo.comMAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting CompoundsSee More Headlines Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:MAIA CUSIPN/A CIKN/A Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-520.95% Return on Assets-233.25% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book73.33Miscellaneous Outstanding Shares14,210,000Free Float6,116,000Market Cap$31.26 million OptionableNot Optionable Beta0.16 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Vlad Vitoc M.B.A. (Age 53)M.D., Co-Founder, President, CEO & Chairman of the Board of Directors Comp: $715.55kDr. Sergei M. Gryaznov Ph.D. (Age 64)Chief Scientific Officer Comp: $524.77kMr. Jeffrey C. HimmelreichHead of FinanceLinda MoreiraCompany SecretaryKey CompetitorsTheratechnologiesNASDAQ:THTXSELLAS Life Sciences GroupNASDAQ:SLSeFFECTOR TherapeuticsNASDAQ:EFTRBiora TherapeuticsNASDAQ:BIORAcurx PharmaceuticalsNASDAQ:ACXPView All CompetitorsInsiders & InstitutionsStan SmithBought 170,940 shares on 3/14/2024Total: $199,999.80 ($1.17/share)Vanguard Group Inc.Bought 80,659 shares on 3/11/2024Ownership: 1.226%Vanguard Group Inc.Bought 80,659 shares on 2/15/2024Ownership: 1.226%Bridgeway Capital Management LLCBought 24,100 shares on 2/15/2024Ownership: 0.533%Citadel Advisors LLCBought 57,473 shares on 2/15/2024Ownership: 0.404%View All Insider TransactionsView All Institutional Transactions MAIA Stock Analysis - Frequently Asked Questions Are investors shorting MAIA Biotechnology? MAIA Biotechnology saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 508,500 shares, an increase of 30.8% from the February 29th total of 388,800 shares. Based on an average daily volume of 424,500 shares, the short-interest ratio is currently 1.2 days. Approximately 4.2% of the shares of the stock are short sold. View MAIA Biotechnology's Short Interest. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) posted its earnings results on Monday, May, 8th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02. Who are MAIA Biotechnology's major shareholders? MAIA Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.23%), Vanguard Group Inc. (1.23%), Bridgeway Capital Management LLC (0.53%) and Citadel Advisors LLC (0.40%). Insiders that own company stock include Cristian Luput, Joseph F Mcguire, Ramiro Guerrero, Stan Smith and Vlad Vitoc. View institutional ownership trends. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:MAIA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.